Pfizer Inc. is pleased to announce that the US Food and Drug Administration has approved BRAFTOVI® (encorafenib) for a new indication.

The following information is for State Society review:

Approval information: https://www.pfizer.com/news/press-release/press-release-detail/u_s_fda_approves_braftovi_encorafenib_in_combination_with_cetuximab_for_the_treatment_of_brafv600e_mutant_metastatic_colorectal_cancer_crc_after_prior_therapy

Prescribing Information: www.BraftoviPI.com